BioXcel Therapeutics, Inc. (BTAIQ) stock
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
BioXcel Therapeutics, Inc. saw revenue fall 14.5% to $742.00K over the twelve months to Jun 30, 2026. Free cash flow was -$50.90M. At the latest close the market valued the company at $757.50K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $757.50K
- P/E ratio
- –
- Price to sales
- 1.02
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -6720.00%
Fundamentals
- Revenue
- $742.00K
- Net income
- -$70.86M
- EPS, diluted
- -$3.78
- Free cash flow
- -$50.90M
- Book value per share
- -$3.81
- Diluted shares
- 30M
Trading
- Previous close
- $0.03
- Open
- $0.02
- Day's range
- $0.02 – $0.03
- Volume
- 146,572
- Average volume (20 days)
- 396,018
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | BTAIQ | S&P 500 | Difference | BTAIQ per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -56.9% | +0.6% | −57.5 pts | ||
| 3 months | -97.2% | +3.4% | −100.6 pts | ||
| Year to date | -98.4% | +13.3% | −111.7 pts | ||
| 1 year | -98.9% | +16.6% | −115.5 pts | ||
| 3 years | -99.9% | +86.4% | −186.3 pts | -91.6% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.8 pts | -86.0% | +12.7% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BioXcel Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- Update
About BioXcel Therapeutics
Pharmaceutical Preparations
BioXcel Therapeutics, Inc. is a biopharmaceutical company that develops medicines in neuroscience, alongside its wholly owned subsidiary OnkosXcel Therapeutics, which focuses on immuno-oncology. The company utilizes a proprietary artificial intelligence platform designed to identify new therapeutic indications from existing approved drugs or clinical candidates to treat disorders with unmet medical needs. Its commercialized product is IGALMI, a sublingual film formulation of dexmedetomidine approved for the acute treatment of agitation linked to schizophrenia or bipolar I or II disorder in adults. Its clinical pipeline includes BXCL501 for acute agitation across neuropsychiatric conditions and BXCL701 for various aggressive tumors. Target customers encompass healthcare providers, hospitals, integrated delivery networks, and patients requiring agitation management.
Company profile, executives and historyBioXcel Therapeutics stock: common questions
What is BioXcel Therapeutics's stock price?
BTAIQ closed at $0.03 on Oct 19, 2026, down 13.49% on the day.
What is BioXcel Therapeutics's market cap?
BioXcel Therapeutics was worth $757.50K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is BTAIQ's P/E ratio?
BioXcel Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.78), so it has no meaningful P/E ratio.
How much revenue does BioXcel Therapeutics make?
BioXcel Therapeutics reported revenue of $742.00K for the twelve months to Jun 30, 2026, down 14.5% from a year earlier.
Does BioXcel Therapeutics pay a dividend?
No. BioXcel Therapeutics has not paid a cash dividend over the last twelve months.
How has BTAIQ stock performed over the past year?
Including dividends, BTAIQ returned -98.9% over the past year, against +16.6% for the S&P 500.
Who are BioXcel Therapeutics's competitors?
Companies most similar to BioXcel Therapeutics by business, industry and size include IGC, SPRB, VCNX, OVID, MNOV.
See a number that looks wrong?